Monoclonal antibody (mAb) immunogenicity testing evaluates the anti-drug antibody (ADA) and neutralizing antibody (NAb) responses that therapeutic antibodies may trigger in patients, helping sponsors manage risks to safety, pharmacokinetics, and efficacy. Using validated, multi-tiered assay platforms aligned with FDA, EMA, ICH, and USP <1106> expectations, accredited third-party laboratories support immunogenicity assessment from preclinical development through post-marketing surveillance. This article outlines the sample types, testing items, analytical methods, validation criteria, and regulatory applications of mAb immunogenicity testing.
Technical Overview
Immunogenicity refers to the capacity of a therapeutic monoclonal antibody to induce an unwanted immune response, most commonly manifested as the generation of anti-drug antibodies (ADAs). Even humanized and fully human antibodies can be immunogenic due to residual non-human framework sequences, aggregation, degradation products, glycosylation heterogeneity, formulation excipients, leachables, route and frequency of administration, and patient-specific factors such as HLA haplotype, underlying disease, and concomitant medication.
Clinical consequences of ADA development include altered pharmacokinetics (accelerated drug clearance or, less commonly, prolonged exposure through immune complex formation), reduced efficacy due to neutralization of the therapeutic antibody, hypersensitivity and infusion reactions, and rare but severe outcomes when ADAs cross-react with endogenous protein counterparts. Because these effects can compromise both patient safety and product performance, immunogenicity testing is a regulatory expectation throughout the product lifecycle.
The analytical strategy follows a risk-based, multi-tiered approach recommended by the U.S. FDA (Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products), the EMA (Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins), ICH S6(R1) (Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals), and the USP General Chapter <1106> on immunoassays for anti-drug antibody detection:
- Screening (detection) assay to identify potentially ADA-positive samples
- Confirmatory assay to demonstrate specificity using competitive inhibition with excess unlabeled drug
- Titration assay to estimate the magnitude of the ADA response
- Characterization assays, including isotyping and neutralizing antibody (NAb) assessment
Testing Samples
Serum Samples
Serum is the preferred matrix for immunogenicity evaluation. Blood is collected in plain or separator tubes, allowed to clot under controlled conditions, and centrifuged to separate serum. Typical collection time points include a pre-dose baseline, scheduled post-dose visits aligned with pharmacokinetic trough sampling, and follow-up visits to characterize ADA persistence and resolution. Generally, 200 to 500 µL of serum per time point is sufficient for the full assay cascade. Samples should be stored at -60 °C or below in aliquots to avoid repeated freeze-thaw cycles, and shipping must maintain a documented cold chain.
Plasma Samples
Plasma collected with EDTA, heparin, or citrate anticoagulants can be used when validated for the specific assay format, since anticoagulants and assay format may influence background signal. Matrix equivalence between serum and plasma must be demonstrated during method development, and the same matrix should be used consistently for clinical sample analysis.
Controls and Reference Materials
Each assay run includes a negative control prepared from pooled treatment-naive human serum and positive controls, typically an affinity-purified anti-drug antibody (for example, a rabbit or goat polyclonal antibody or a murine monoclonal surrogate). High and low positive controls bracket the assay cut point and are used for system suitability monitoring, run acceptance, and sensitivity determination. Special populations, such as autoimmune patients or donors with pre-existing antibodies, rheumatoid factor, or heterophilic antibody interference (including human anti-mouse antibodies), should be represented when relevant to the intended patient population.
Testing Items
Immunogenicity testing for monoclonal antibody drugs typically encompasses the following portfolio of analyses:
- Binding ADA detection: identification of samples containing antibodies that bind the therapeutic antibody, reported as treatment-emergent, treatment-boosted, or persistent ADA status
- Confirmatory ADA testing: competitive binding with unlabeled drug to confirm specificity and reduce false positives
- ADA titer determination: semi-quantitative estimation of antibody levels using serial dilution to the assay cut point
- ADA isotype characterization: classification of IgG, IgM, or IgE responses where relevant to safety interpretation
- Neutralizing antibody (NAb) assessment: detection of ADAs that inhibit the binding or functional activity of the drug at its target
- Complementary drug concentration measurement: coordinated pharmacokinetic analysis to interpret ADA results in the context of drug exposure and assay interference
Testing Methods
Screening Assay
The screening assay employs a validated format, most commonly a bridging immunoassay in which the therapeutic antibody serves as both capture and detection reagent (labeled drug). Results are compared against a statistically derived screening cut point, typically set at the 95th percentile of treatment-naive donor responses, targeting an approximately 5% false-positive rate. Cut points may be fixed or floating depending on inter-plate variability observed during validation.
Confirmatory Assay
Presumptive positive samples are retested in the presence of excess unlabeled drug. A statistically significant reduction in signal (for example, 50% inhibition relative to the uninhibited control) confirms specific binding to the therapeutic antibody. The confirmatory cut point is generally set to achieve an approximately 1% false-positive rate.
Analytical Platforms
Several complementary platform technologies are available, and platform selection depends on required sensitivity, drug tolerance, target interference, and the nature of the ADA response:
- Bridging ELISA: a robust, widely adopted colorimetric format suitable for detecting bivalent IgG and IgM ADAs
- Electrochemiluminescence immunoassay (ECLIA): offers enhanced sensitivity, wide dynamic range, low background, and improved tolerance to residual circulating drug
- Surface plasmon resonance (SPR): a label-free technique capable of detecting low-affinity and monovalent antibodies as well as ADA-drug immune complexes, and less affected by high drug concentrations
- Radiolabeled immunoassays: applied in specific circumstances where other formats encounter matrix or interference limitations
Neutralizing Antibody Assays
NAb assays evaluate whether ADAs inhibit drug function. Where feasible, cell-based assays are preferred because they reflect the drug's mechanism of action; formats include target-driven reporter gene assays, cell proliferation or cytotoxicity inhibition assays, and ligand-blocking assays. When cell-based formats are not scientifically justified, competitive ligand-binding assays provide an alternative. NAb assay cut points and controls are established using the same statistical principles as binding ADA assays.
Method Validation
Methods are validated in the intended species matrix in accordance with USP <1106>, USP <1106.1> principles for neutralizing antibody assays, and FDA and EMA immunogenicity guidance. Core validation parameters include:
- Cut point establishment (screening and confirmatory) using an adequate population of treatment-naive donor samples
- Sensitivity, generally demonstrated in the low ng/mL range using the affinity-purified positive control antibody
- Drug interference (drug tolerance) and soluble target interference assessments at clinically relevant concentrations
- Precision (intra-run and inter-run) for both positive and negative controls
- Specificity, selectivity, and matrix effects across individual donor sera
- Robustness, minimum required dilution (MRD), and sample stability under storage, freeze-thaw, and bench-top conditions
- Titration assay linearity and reproducibility
Testing should be performed under a GLP-aligned or equivalent quality system in ISO/IEC 17025-accredited third-party laboratories or facilities with equivalent quality management systems, with bioanalytical data suitable for inclusion in IND, BLA, NDA, or MAA submissions.
Applications
Immunogenicity testing supports decision-making across the entire development and commercialization continuum for monoclonal antibody therapeutics:
- Preclinical and IND-enabling programs: evaluation of ADA incidence in toxicology and pharmacology studies to interpret exposure, pharmacodynamic, and safety findings
- Clinical trials (Phases I through III): systematic ADA monitoring, incidence reporting, and correlation of ADA status with pharmacokinetics, efficacy, and adverse events for regulatory submissions and product labeling
- Biosimilar development: comparative immunogenicity studies demonstrating similarity to the reference medicinal product
- Manufacturing and process changes: comparability exercises assessing whether process, formulation, or site changes alter immunogenicity risk
- Post-marketing surveillance: monitoring of ADA incidence in broader and special populations, including pediatric patients, autoimmune cohorts, and patients receiving chronic or combination therapy
- Root cause investigation: assessment of ADA responses following hypersensitivity events or unexpected loss of efficacy
FAQ
Why is immunogenicity testing required for monoclonal antibody drugs?
Regulatory authorities, including the FDA and EMA, expect a risk-based immunogenicity evaluation for all biotherapeutics because ADAs can reduce drug exposure and efficacy, cause infusion and hypersensitivity reactions, and occasionally neutralize endogenous proteins. Immunogenicity data are integral to benefit-risk assessment, dosing strategy, patient monitoring language, and product labeling.
What sensitivity should a screening assay achieve?
Current regulatory guidance expects screening assay sensitivity in the low hundreds of ng/mL or better, with many validated platforms achieving low ng/mL sensitivity using high-affinity positive control antibodies. The required sensitivity is justified relative to the expected clinical impact of low ADA concentrations and is confirmed in the study species matrix at the minimum required dilution.
How is the assay cut point determined?
Cut points are derived statistically from treatment-naive donor samples, typically using the 95th percentile for the screening cut point (approximately 5% false-positive rate) and the 99th percentile for the confirmatory cut point (approximately 1% false-positive rate). Outlier evaluation and appropriate parametric or non-parametric methods are applied, and the final cut point may be adjusted based on validation and in-study performance.
How are neutralizing antibodies detected?
Neutralizing antibodies are measured in cell-based assays that reflect the drug's mechanism of action, such as reporter gene or cell proliferation inhibition formats, or in competitive ligand-binding assays when a cell-based approach is not scientifically appropriate. Confirmed ADA-positive samples are prioritized for NAb testing according to the product's immunogenicity risk assessment.
How are false-positive results controlled?
False positives arising from heterophilic antibodies, rheumatoid factor, matrix effects, or non-specific binding are controlled through assay format design (such as bridging formats), blocking reagents, sample pre-treatment where justified, the multi-tiered confirmation strategy, and rigorous validation of specificity and selectivity across individual donor matrices.
How should samples be collected and shipped?
Serum or validated plasma samples should be collected at baseline and at protocol-defined post-dose time points, processed promptly, aliquoted, and stored at -60 °C or below with a documented, temperature-monitored cold chain during shipment to the testing laboratory to preserve sample integrity.